secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029926
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q4 2023: oncology revenue $107.9M, ZYNRELEF record $5.6M, 2024 guidance reaffirmed
--------------------------------------------------------------------------------

- Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.
- ZYNRELEF Q4 net product sales record $5.6M (up from $3.9M Q4 2022); acute care franchise sales $6.1M.
- Gross margin improved to 71% in Q4 from 58% a year ago; cash and equivalents $80.4M at year-end.
- FDA approved expanded ZYNRELEF label covering ~13M annual procedures; CrossLink partnership adds up to 650 sales reps.
- 2024 guidance: product revenues $138-158M, adjusted EBITDA $(22)-$3M; VAN program PAS submission on track for Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/0000950170-24-029926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/hrtx-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer